Anti-IL-5 Therapy in Bullous Pemphigoid (BP)

NCT01705795 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Pemphigoid, Bullous

Interventions

DRUG: Mepolizumab (a-IL-5 antibody)
DRUG: Placebo

Sponsor

Insel Gruppe AG, University Hospital Bern